Health and Human Services Secretary Robert F. Kennedy Jr. said any staffers in the department who are “working for the ...

The Trump administration's decision to pause enforcement of an anti-bribery law raised the specter that drugmakers could ...

Currrax Pharmaceuticals over-performed its 2024 revenue goal and has exceeded 50% year-over-year revenue growth for its ...

When done safely and securely, automated inbound engagement can provide significant benefits for pharmaceutical companies.

Vaccine policy, Medicare drug negotiations, and a potential DTC advertising ban will all fall under Kennedy’s purview as HHS ...

A quirk in the website OpenSecrets has given RFK Jr. a chance to misleadingly portray Sen. Bernie Sanders as receiving big ...

Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...

A small and financially opaque drug research nonprofit group based in Ohio has managed to get its research cited extensively in high-prestige publications such as the New York Times, Wall Street ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

U.S. President Donald Trump’s threats to slap tariffs on medicines could rattle an industry that has become a cornerstone of ...

As the demand for novel therapies and personalized medicine surges, leaders are uniquely positioned to create a culture of creativity, collaboration and innovation.

Like many of President Donald Trump's appointees, Robert F. Kennedy, Jr., is promising to bring bold change and to “Make America Healthy Again.” ...